Financial Results | Minerva 2025 Half-Year Net Loss USD 7.01 Million

Minerva(NERV) posted the Q2 of its 2025 financial results on 8/14/2025, reporting net loss of USD 7.01 million in the first half of the year, narrowing 58.27% from USD -16.80 million year over year. The EPS is USD -0.93 in the first half of the year, compare with USD -2.22 last period.

[Detailed Data]

Million USD	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Total Operating Expenses	3.37	3.90	4.52	4.37
Operating Income	-3.37	-3.90	-4.52	-4.37
Net Income	-3.26	-3.75	-4.27	22.51
Net Income Attributable to Common Shareholders	-3.26	-3.75	-4.27	22.51
EPS(USD)	-0.43	-0.5	-0.6109	2.97

[Company Profile]
Minerva Neurosciences, Inc. was incorporated under the name Cyrenaic Pharmaceuticals, Inc. under the laws of the State of Delaware on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc. As a result of the merger, or the Sonkei Merger, the company has the rights to develop, sell and import MIN-101 and MIN-117 globally, excluding most of Asia, pursuant to license agreements with Mitsubishi Tanabe Pharma Corporation. The company further expanded its product candidate portfolio in February 2014 by acquiring the shares of Mind-NRG SA, or Mind-NRG, which has exclusive rights to develop and commercialize MIN-301, or the Mind-NRG Acquisition. The company is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases. The company's lead product candidates are MIN-101, a compound it is developing for the treatment of patients with schizophrenia, and MIN-117, a compound the company is developing for the treatment of patients suffering from major depressive disorder, or MDD.